Hereditary Hemochromatosis Clinical Trial
Official title:
A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
This study is a Phase 2 multicenter, randomized, placebo controlled, single-blind study. The primary objective of the study is to compare the effect of weekly dosing of LJPC-401 (synthetic human hepcidin) versus placebo on transferrin saturation (TSAT) in an adult hereditary hemochromatosis patient population.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Unknown status |
NCT01398644 -
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
|
Phase 3 | |
| Terminated |
NCT05238207 -
A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers
|
Phase 1 | |
| Completed |
NCT04202965 -
PTG-300 in Subjects With Hereditary Hemochromatosis
|
Phase 2 | |
| Enrolling by invitation |
NCT05742035 -
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
|
N/A | |
| Completed |
NCT03203850 -
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
|
Phase 2 | |
| Completed |
NCT00068159 -
Cardiac Function in Patients With Hereditary Hemochromatosis
|
||
| Completed |
NCT00395629 -
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00440986 -
Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis
|
Phase 2/Phase 3 |